A Atazanavir sulfate, BMS-232632-05, CGP-73547, Reyataz, Zrivada CEP of the European Pharmacopoeia monograph is often referred to as a Atazanavir sulfate, BMS-232632-05, CGP-73547, Reyataz, Zrivada Certificate of Suitability (COS). The purpose of a Atazanavir sulfate, BMS-232632-05, CGP-73547, Reyataz, Zrivada CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Atazanavir sulfate, BMS-232632-05, CGP-73547, Reyataz, Zrivada EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Atazanavir sulfate, BMS-232632-05, CGP-73547, Reyataz, Zrivada to their clients by showing that a Atazanavir sulfate, BMS-232632-05, CGP-73547, Reyataz, Zrivada CEP has been issued for it. The manufacturer submits a Atazanavir sulfate, BMS-232632-05, CGP-73547, Reyataz, Zrivada CEP (COS) as part of the market authorization procedure, and it takes on the role of a Atazanavir sulfate, BMS-232632-05, CGP-73547, Reyataz, Zrivada CEP holder for the record. Additionally, the data presented in the Atazanavir sulfate, BMS-232632-05, CGP-73547, Reyataz, Zrivada CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Atazanavir sulfate, BMS-232632-05, CGP-73547, Reyataz, Zrivada DMF.
A Atazanavir sulfate, BMS-232632-05, CGP-73547, Reyataz, Zrivada CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Atazanavir sulfate, BMS-232632-05, CGP-73547, Reyataz, Zrivada CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Atazanavir sulfate, BMS-232632-05, CGP-73547, Reyataz, Zrivada suppliers with CEP (COS) on PharmaCompass.